News

Carmen Kosicek, MSN, PMHNP-BC, and team share their excitement over potential new options pending the FDA's Advisory Committee meeting.

Rakesh Jain, MD, shares more about the recent approval of Austedo XR for the treatment of tardive dyskinesia and Huntington disease chorea control.

Investigators have dosed the first participant in a new study investigating the neurophysiological effects of BPL-003.

A lead educator and clinical consultant in the Lykos Therapeutics MDMA Therapist Education Program discusses MDMA-assisted therapy’s potential.

Some clinicians are skeptical about the potential of MDMA-assisted therapy...

If approved, how will MDMA-assisted therapy impact clinical psychiatry? The CEO of Lykos Therapeutics shares her thoughts.

In advance of the June 4 FDA Advisory Committee Meeting on MDMA-assisted therapy, we sat down with Alejandra Alva, MD, to get his first impressions.

The importance of compassion.

Answer a quick question on psychedelics!

Answer a quick question about psychedelics!

In this CME article, learn more about common clinical conditions, consultation questions, and challenges in the field of critical care psychiatry.

Answer a quick question on psychedelics!

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the treatment for depressive symptoms in this patient population.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the efficacy and tolerability of the investigational schizophrenia treatment.

"Not in the hands of boys, but in their eyes, Shall shine the holy glimmers of goodbyes."

How effective is this treatment in real-world clinical settings? Experts explore this in a poster presented at the 2024 ASCP Annual Meeting.

The need for effective leadership is apparent.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study analyzing the treatment’s safety and efficacy in this patient population.

A poster presented at the 2024 ASCP Annual Meeting discusses the results of a systematic literature review.

Answer a quick question on psychedelics!

Learn more about the potential of MDMA-assisted psychotherapy.

Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.

Research on MDD treatments seltorexant and Spravato (esketamine) CIII nasal spray shared at 2024 ASCP Annual Meeting.

How does the Voice Lab relate to psychotherapy?

An expert shares 7 principles for clinicians to consider when prescribing multiple medications for a patient.

The FDA has approved Austedo XR as a once-daily pill treatment option for tardive dyskinesia and Huntington disease chorea control.

Anita H. Clayton, MD, gives a preview of her upcoming poster presentation at the 2024 ASCP Annual Meeting.

Joseph F. Goldberg, MD, gives a preview of his upcoming panel presentation at the 2024 ASCP Annual Meeting.

Anita H. Clayton, MD, welcomes us all to the 2024 ASCP Annual Meeting!

Onyda XR is the first and only liquid nonstimulant ADHD medication approved in the US and the only approved nonstimulant ADHD medication with nighttime dosing.